ClinicalTrials.gg
Active, not recruitingNCT06858878MARITIME-2Updated Dec 31, 2025

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

A Phase 3 interventional study of Maridebart cafraglutide and Placebo in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, sponsored by Amgen. Active, not recruiting at 187 sites in 13 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,105
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Diabetes Mellitus, Type 2 by Amgen — 3 open to participants now, 7 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Amgen.

Enrollment
2nd of 16
1,105 · median 221
Started
2025
with 2 others
Phase 3
5 of 16
2 open now
Registered
11th of 16
by date

Among the 16 studies in Diabetes Mellitus, Type 2 by Amgen, this one is the 2nd largest by enrollment, is one of 3 that started in 2025, is one of 5 in phase 3, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 16 studies in Diabetes Mellitus, Type 2 by Amgen are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Diabetes Mellitus, Type 2 by Amgen, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Keywords

  • Type 2 Diabetes Mellitus
  • T2DM
  • Obesity
  • Overweight
  • Maridebart Cafraglutide
  • AMG 133
  • MariTide
  • Chronic Weight Management
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • ≥ 27 kg/m\^2.
  • History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.
  • Diagnosis of T2DM.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus.
  • Self-reported change in body weight > 5 kg within 90 days before screening.
  • Proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment.
  • Obesity induced by other endocrinologic disorders.
  • Family (first-degree relative[s]) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2.
  • History of chronic pancreatitis or history of acute pancreatitis within 180 days before screening.
  • History of unstable major depressive disorder (MDD) or other severe psychiatric disorder within 2 years before screening.
  • Lifetime history of suicide attempt.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,105 participants (actual)

Study arms

  • Experimental
    Maridebart Cafraglutide High Dose

    Participants will receive maridebart cafraglutide high dose subcutaneously (SC) for 72 weeks.

    Drug: Maridebart cafraglutide

  • Experimental
    Maridebart Cafraglutide Medium Dose

    Participants will receive maridebart cafraglutide medium dose SC for 72 weeks.

    Drug: Maridebart cafraglutide

  • Experimental
    Maridebart Cafraglutide Low Dose

    Participants will receive maridebart cafraglutide low dose SC for 72 weeks.

    Drug: Maridebart cafraglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo SC for 72 weeks.

    Drug: Placebo

Interventions

  • Maridebart cafraglutide will be adminstered SC.

    Also known as: AMG 133, MariTide

  • DrugPlacebo

    Placebo will be adminstered SC.

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight at Week 72

    Time frame: Baseline and Week 72

Secondary outcomes

  1. Change from Baseline in Waist Circumference at Week 72

    Time frame: Baseline and Week 72

  2. Participant achieving ≥ 5% reduction in body weight from baseline at week 72

    Time frame: Baseline and Week 72

  3. Participant achieving ≥ 10% reduction in body weight from baseline at week 72

    Time frame: Baseline and Week 72

  4. Participant achieving ≥ 15% reduction in body weight from baseline at week 72

    Time frame: Baseline and Week 72

  5. Change from Baseline in Systolic Blood Pressure (SBP) at Week 72

    Time frame: Baseline and Week 72

  6. Percent Change from Baseline in Fasting Triglycerides at Week 72

    Time frame: Baseline and Week 72

  7. Change from Baseline in Fasting Plasma Glucose at Week 72

    Time frame: Baseline and Week 72

  8. Change from Baseline in Hemoglobin A1c (HbA1c) at Week 72

    Time frame: Baseline and Week 72

  9. Participant achieving HbA1c < 7% at week 72

    Time frame: Week 72

  10. Change from Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score at Week 72

    Time frame: Baseline and Week 72

  11. Change from Baseline in Body Weight at Week 72

    Time frame: Baseline and Week 72

  12. Participant achieving ≥ 20% reduction in body weight from baseline at week 72

    Time frame: Baseline and Week 72

  13. Change from Baseline in Body Mass Index (BMI) at Week 72

    Time frame: Baseline and Week 72

  14. Participant achieving HbA1c ≤ 6.5% at week 72

    Time frame: Week 72

  15. Participant achieving HbA1c < 5.7%, at week 72

    Time frame: Week 72

  16. Percent Change from Baseline in Fasting Insulin at Week 72

    Time frame: Baseline and Week 72

  17. Percent Change from Baseline in High-sensitivity C-reactive Protein (hs-CRP) at Week 72

    Time frame: Baseline and Week 72

  18. Change from Baseline in Urine Albumin-to-creatinine Ratio (uACR) at Week 72

    Time frame: Baseline and Week 72

  19. Percent Change from Baseline at Week 72 in Fasting Concentration of Total Cholesterol

    Time frame: Baseline and Week 72

  20. Percent Change from Baseline at Week 72 in Fasting Concentration of Non-high-density Lipoprotein Cholesterol (non-HDL-C)

    Time frame: Baseline and Week 72

  21. Percent Change from Baseline at Week 72 in Fasting Concentration of Low-density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline and Week 72

  22. Percent Change from Baseline at Week 72 in Fasting Concentration of Very-low-density Lipoprotein Cholesterol (VLDL-C)

    Time frame: Baseline and Week 72

  23. Percent Change from Baseline at Week 72 in Fasting Concentration of High-density Lipoprotein Cholesterol (HDL-C)

    Time frame: Baseline and Week 72

  24. Change from Baseline in Diastolic Blood Pressure DBP at Week 72

    Time frame: Baseline and Week 72

  25. Change from Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Physical Function Domain Score at Week 72

    Time frame: Baseline and Week 72

  26. Number of Participants who Experienced Treatment-emergent Adverse Events

    Time frame: Up to Week 84

  27. Number of Participants who Experienced Serious Adverse Events

    Time frame: Up to Week 84

  28. Plasma Concentration of Maridebart Cafraglutide at Week 72

    Time frame: Week 72

07

Study locations

187 sites

Showing the first 100 of 187 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 22 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 22 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2025
First posted
Mar 5, 2025
StartActual
Mar 17, 2025
Primary completionEst.
Jan 21, 2027
CompletionEst.
Apr 16, 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06858878
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Mar 17, 2025
Primary completion
Jan 21, 2027 (estimated)
Completion
Apr 16, 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion